| Dr Suntrea Tg Hammer, MD | |
|
5323 Harry Hines Blvd, Dallas, TX 75390-7201 | |
| (214) 590-6585 | |
| Not Available |
| Full Name | Dr Suntrea Tg Hammer |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 17 Years |
| Location | 5323 Harry Hines Blvd, Dallas, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518152370 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ut Southwestern University Hospital - William P. Clements Jr. | Dallas, TX | Hospital |
| Parkland Health & Hospital System | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Texas Southwestern Medical Center | 0648188250 | 2588 |
News Archive
With the new knowledge that providing antiretroviral treatment to people living with HIV would "contribut[e] to a sharp slowdown in the spread of the virus," "scaling up treatment now may prove to be the least expensive option if we want to bring this deadly pandemic, which still infects 1.8 million people every year, under control," Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria writes in the Guardian's "Poverty Matters Blog."
Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.
Using a combination of therapies and cell grafts, a team of University of California, San Diego (UCSD) School of Medicine researchers has promoted significant regeneration of nerve cells in rats with spinal cord injury.
A study published online on May 24th in the Journal of Experimental Medicine (www.jem.org) suggests that boosting the abundance of one of the body's own proteins might be more effective than antibiotic treatment at fighting off a common meningitis-causing bacterium (E. coli K1).
Children under age 5 who underwent minor surgery requiring anesthesia had a 26 percent increased risk of later diagnosis with a mental disorder. However, the timing of the procedure did not affect this risk, according to a new study at Columbia University's Mailman School of Public Health and College of Physicians and Surgeons.
› Verified 6 days ago
| Entity Name | University Of Texas Southwestern Medical Center At Dallas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
With the new knowledge that providing antiretroviral treatment to people living with HIV would "contribut[e] to a sharp slowdown in the spread of the virus," "scaling up treatment now may prove to be the least expensive option if we want to bring this deadly pandemic, which still infects 1.8 million people every year, under control," Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria writes in the Guardian's "Poverty Matters Blog."
Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.
Using a combination of therapies and cell grafts, a team of University of California, San Diego (UCSD) School of Medicine researchers has promoted significant regeneration of nerve cells in rats with spinal cord injury.
A study published online on May 24th in the Journal of Experimental Medicine (www.jem.org) suggests that boosting the abundance of one of the body's own proteins might be more effective than antibiotic treatment at fighting off a common meningitis-causing bacterium (E. coli K1).
Children under age 5 who underwent minor surgery requiring anesthesia had a 26 percent increased risk of later diagnosis with a mental disorder. However, the timing of the procedure did not affect this risk, according to a new study at Columbia University's Mailman School of Public Health and College of Physicians and Surgeons.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Suntrea Tg Hammer, MD Po Box 845347, Dallas, TX 75284-5347 Ph: (214) 590-6585 | Dr Suntrea Tg Hammer, MD 5323 Harry Hines Blvd, Dallas, TX 75390-7201 Ph: (214) 590-6585 |
News Archive
With the new knowledge that providing antiretroviral treatment to people living with HIV would "contribut[e] to a sharp slowdown in the spread of the virus," "scaling up treatment now may prove to be the least expensive option if we want to bring this deadly pandemic, which still infects 1.8 million people every year, under control," Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria writes in the Guardian's "Poverty Matters Blog."
Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.
Using a combination of therapies and cell grafts, a team of University of California, San Diego (UCSD) School of Medicine researchers has promoted significant regeneration of nerve cells in rats with spinal cord injury.
A study published online on May 24th in the Journal of Experimental Medicine (www.jem.org) suggests that boosting the abundance of one of the body's own proteins might be more effective than antibiotic treatment at fighting off a common meningitis-causing bacterium (E. coli K1).
Children under age 5 who underwent minor surgery requiring anesthesia had a 26 percent increased risk of later diagnosis with a mental disorder. However, the timing of the procedure did not affect this risk, according to a new study at Columbia University's Mailman School of Public Health and College of Physicians and Surgeons.
› Verified 6 days ago
Dr. Jaime Albert Campbell, M.D., M.S. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3500 Gaston Ave, Baylor University Medical Center, Dept Of Pathology, Dallas, TX 75246 Phone: 214-820-3772 | |
Brianne Flynn, Pathology Medicare: Not Enrolled in Medicare Practice Location: 2355 N Stemmons Fwy, Dallas, TX 75207 Phone: 214-920-5900 | |
Dr. Timothy Joseph Kirtek, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd Stop 7200, Dallas, TX 75390 Phone: 214-648-3433 | |
Keith Allen Wharton Jr., MD PHD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-1620 Fax: 214-648-4080 | |
Dinesh Rakheja, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-1620 Fax: 214-648-4080 | |
Dr. Emmy L. Kiss, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-590-6494 | |
Thomas Hugh Mcconnell, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 3401 Lee Pkwy Apt 304, Dallas, TX 75219 Phone: 214-363-2221 Fax: 214-363-2228 |